Authors

Latest:

Dr. Al-Niaimi Discusses Cytoreductive Surgery in Ovarian Cancer

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses cytoreductive surgery in ovarian cancer.

Ahmed O. Kaseb, MD

Latest:

Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCC

Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.

Ahmet Dogan, MD, PhD

Latest:

Dr. Dogan on Updated WHO Classifications in DLBCL

Ahmet Dogan, MD, PhD, chief of Hematopathology Service, Departments of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, discusses the updated World Health Organization (WHO) classification and how it impacts treatment decisions for patients with diffuse large B-cell lymphoma (DLBCL).

Aileen M. Soper, BA

Latest:

NOW Initiative: Payer & Provider Collaborations in Oncology Benefits Management

Payers recognize the need to expand benefits management for oncology but struggle to find effective solutions amid the complexity of available therapies and skepticism from oncologists, who are facing their own set of economic pressures. The National Oncology Working Group (NOW) Initiative is trying to change the sometimes adversarial relationship between payers and oncologists through a collaborative model.

Aiwu Ruth He, MD

Latest:

Dr. He on the Results of the LEGACY Study Examining Y-90 in HCC

Ruth Aiwu He, MD, PhD, discusses the results of the LEGACY study in patients with hepatocellular carcinoma.

Aiwu Ruth He, MD, PhD

Latest:

Dr He on the Evaluation of Camrelizumab Plus Rivoceranib in Unresectable HCC

Aiwu Ruth He, MD, PhD, discusses the evaluation of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Ajai Chari, MD, PhD

Latest:

Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai

Ajai Chari, MD, Icahn School of Medicine, Mount Sinai

Ajai Chari, MD

Latest:

Dr Chari on the Selection of BCMA-Targeted Therapies Within Multiple Myeloma

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

Ajai Chari, MD, Mount Sinai Hospital

Latest:

Dr Chari on the MonumenTAL-1 Trial Examining Talquetamab in Multiple Myeloma

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Ajay K. Gopal, MD, FACP

Ajay K. Nooka, MD, MPH, FACP

Latest:

Dr Nooka on Integrating Bispecific Antibodies Into the Community Treatment Paradigm for Multiple Myeloma

Ajay K. Nooka, MD, MPH, FACP, discusses the integration of bispecific antibodies into the community treatment paradigm for multiple myeloma.

Ajay S. Behl, PhD

Latest:

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

Ajay V. Maker, MD, FACS

Latest:

New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI Metastases

Despite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.

Ajjai Shivaram Alva, MBBS

Latest:

Dr. Alva on the Shift Toward Combination Therapy in mRCC

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Aju Mathew, MD, MPhil

Latest:

Staying Afloat When the Floodgates Open

It is quite easy to be drowned in the rising floodwaters of hematology and medical oncology, especially when you start training.

Akash Patnaik, MD, PhD

Latest:

Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Akhil Kumar, MD

Latest:

Targeted Therapies in Advanced Renal Cell Cancer: A Critical Review

In order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.

Akihiko Shimomura, MD, PhD

Latest:

Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast Cancer

Akihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.